What is EnsoData?
Headquartered in Madison, Wisconsin, EnsoData specializes in the development of sophisticated software designed to track and analyze vital health metrics, including heart rhythms and glycemic indices. By automating the interpretation of complex physiological signals, the firm enables healthcare providers to make more informed, data-driven clinical decisions. The company's core technology serves as a force multiplier for diagnostic accuracy, effectively bridging the gap between raw patient data and actionable medical insights. As the healthcare industry shifts toward precision medicine and remote monitoring, EnsoData's platform is increasingly viewed as an essential tool for improving patient outcomes and operational efficiency within clinical workflows.
How much funding has EnsoData raised?
EnsoData has raised a total of $50.7M across 5 funding rounds:
Angel/Seed
$550K
Private Equity
$987K
Debt
$150K
Series A
$29M
Series B
$20M
Angel/Seed (2016): $550K with participation from HealthX Ventures
Private Equity (2017): $987K, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Series A (2022): $29M featuring Venture Investors, Zetta Venture Partners, and Inspire Medical Systems
Series B (2025): $20M backed by Zetta Venture Partners, Supermoon Capital, Inspire Medical Systems, and Questa Capital
Key Investors in EnsoData
Zetta Venture Partners
A venture capital firm specializing in zero-to-one capital and hands-on support for AI-native startups, focusing on infrastructure and developer tools.
Supermoon Capital
A venture platform dedicated to supporting visionary founders innovating in the sleep health and wellness categories.
Inspire Medical Systems
A developer of advanced sleep apnea systems utilizing neurostimulation technologies and proprietary algorithms to improve patient breathing patterns.
What's next for EnsoData?
With this latest infusion of capital, EnsoData is well-positioned to accelerate its product roadmap and expand its footprint in the digital health market. The company is expected to focus on deepening its AI capabilities, potentially integrating more diverse physiological data streams to enhance its diagnostic suite. Furthermore, the strategic involvement of specialized healthcare investors suggests a push toward broader commercial adoption and deeper integration with existing hospital information systems. As EnsoData scales, the focus will likely remain on maintaining clinical rigor while navigating the complexities of the evolving healthcare regulatory landscape, ensuring that its AI-native solutions remain at the forefront of medical technology innovation.
See full EnsoData company page
